Author
Listed by name: these papers carry no ORCID for this author, so different people with the same name may be mixed together.
12 papers
Recent·Most cited
F. A. Lempp, T. Volz, E. Cameroni, F. Benigni, J. Zhou, L. E. Rosen, J. Noack, F. Zatta, H. Kaiser, S. Bianchi, G. Lombardo, S. Jaconi, H. Imam, L. B. Soriaga, N. Passini, , M. A. Schmid
This paper identifies a potent anti-HBs mAb, VIR-3434, that neutralizes HBV and HDV and reduces HBsAg and viremia in human liver-chimeric mice.
bioRxiv · Sep 9, 2022Microbiology
Y.-J. Park, D. Pinto, A. C. Walls, Z. Liu, A. De Marco, F. Benigni, F. Zatta, C. Silacci-Fregni, J. Bassi, K. R. Sprouse, A. Addetia, J. E. Bowen, C. Stewart, M. Giurdanella, C. Saliba, , Piccoli
This study shows that hybrid immunity and vaccine boosters provide potent neutralizing activity against Omicron BA.1 and BA.2, while breakthrough infections induce nasal mucosal neutralization and identify an ultrapotent pan-variant antibody.
bioRxiv · May 8, 2022Immunology
J. S. Low, J. Jerak, M. A. Tortorici, M. McCallum, D. Pinto, A. Cassotta, M. Foglierini, F. Mele, R. Abdelnabi, B. Weynand, J. Noack, M. Montiel-Ruiz, S. Bianchi, F. Benigni, N. Sprugasci, , F. Sallusto
The paper identifies monoclonal antibodies that neutralize multiple coronaviruses by targeting the fusion peptide, which becomes exposed upon ACE2 engagement.
bioRxiv · Mar 30, 2022Immunology
T. N. Starr, A. J. Greaney, W. W. Hannon, A. N. Loes, K. Hauser, J. R. Dillen, E. Ferri, A. Ghez Farrell, B. Dadonaite, M. McCallum, K. A. Matreyek, D. Corti, D. Veesler, G. Snell, J. D. Bloom
The paper analyzes epistatic shifts in SARS-CoV-2 RBD mutations across variants to understand how they influence ACE2 binding and future evolution.
bioRxiv · Feb 24, 2022Microbiology
M. McCallum, N. Czudnochowski, L. E. Rosen, S. K. Zepeda, J. E. Bowen, J. R. Dillen, A. Powell, T. Croll, J. Nix, H. W. Virgin, D. Corti, G. Snell, D. Veesler
This study determines the structural basis of SARS-CoV-2 Omicron's immune evasion and receptor engagement through cryo-EM and X-ray crystal structures of the spike and RBD bound to antibodies and ACE2.
bioRxiv · Dec 28, 2021Biochemistry
J. E. Bowen, A. C. Walls, A. Joshi, K. R. Sprouse, C. Stewart, M. A. Tortorici, N. M. Franko, J. K. Logue, I. G. Mazzitelli, S. W. Tiles, K. Ahmed, A. Shariq, G. Snell, N. T. Iqbal, J. Geffner, , D. Veesler
This study shows that vaccines encoding a prefusion-stabilized SARS-CoV-2 spike protein induce higher neutralizing antibody titers and better variant cross-neutralization compared to other vaccines or infection.
bioRxiv · Dec 19, 2021 · PreprintImmunology
Y.-J. Park, A. De Marco, T. N. Starr, Z. Liu, D. Pinto, A. C. Walls, F. Zatta, S. K. Zepeda, J. E. Bowen, K. S. Sprouse, A. Joshi, M. Giurdanella, B. Guarino, J. Noack, R. Abdelnabi, , D. Veesler
This study identifies a broadly neutralizing antibody against sarbecoviruses that targets the ACE2 binding site and shows high resistance to escape mutations.
bioRxiv · Oct 13, 2021Immunology
M. McCallum, A. C. Walls, K. R. Sprouse, J. E. Bowen, L. Rosen, H. V. Dang, A. deMarco, N. Franko, S. W. Tilles, J. Logue, M. C. Miranda, M. Ahlrichs, L. Carter, G. Snell, M. S. Pizzuto, , D. Veesler
This study investigates how delta and kappa SARS-CoV-2 variants evade immune responses by altering antigenic sites and reducing ACE2 binding affinity.
bioRxiv · Aug 11, 2021Immunology
M. A. Tortorici, N. Czudnochowski, T. N. Starr, R. Marzi, A. C. Walls, F. Zatta, J. E. Bowen, S. Jaconi, J. di Iulio, Z. Wang, A. De Marco, S. Zepeda, D. Pinto, Z. Liu, M. Beltramello, , J. Bloom
This paper identifies a human monoclonal antibody that broadly neutralizes SARS-CoV-2 variants and zoonotic sarbecoviruses by targeting a conserved epitope on the spike protein.
bioRxiv · Apr 7, 2021 · PreprintImmunology
A. L. Cathcart, C. Havenar-Daughton, F. A. Lempp, D. Ma, M. Schmid, M. L. Agostini, B. Guarino, J. Di iulio, L. Rosen, H. Tucker, J. Dillen, S. Subramanian, B. Sloan, S. Bianchi, J. Wojcechowskyj, , C. M. Hebner
This paper evaluates the in vitro and in vivo efficacy of dual-action monoclonal antibodies VIR-7831 and VIR-7832 against SARS-CoV-2, showing potent neutralization and reduced viral load in a hamster model.
bioRxiv · Mar 9, 2021 · PreprintImmunology
M. McCallum, A. De Marco, F. Lempp, M. A. Tortorici, D. Pinto, A. C. Walls, M. Beltramello, A. Chen, Z. Liu, F. Zatta, S. Zepeda, J. di Iulio, J. E. Bowen, M. Montiel-Ruiz, J. Zhou, , D. Veesler
The paper identifies a conserved antigenic supersite on the SARS-CoV-2 N-terminal domain recognized by neutralizing antibodies and shows its vulnerability to mutations in variants.
bioRxiv · Jan 14, 2021Immunology
D. Pinto, Y.-J. Park, M. Beltramello, A. C. Walls, M. A. Tortorici, S. Bianchi, S. Jaconi, K. Culap, F. Zatta, A. De Marco, A. Peter, B. Guarino, R. Spreafico, E. Cameroni, J. B. Case, , D. Corti
This study identifies and characterizes a potent neutralizing antibody, S309, against SARS-CoV-2 and related sarbecoviruses, showing its efficacy in preventing viral entry and potential for therapeutic use.
bioRxiv · Apr 7, 2020Immunology